On February 23, Guangdong Pharmaceutical Trading Center issued the notice on viewing the information related to the registered products of Guangdong alliance diclofenac and other drugs purchased in a centralized manner (the first batch). A total of 174 varieties and 1613 products meet the application conditions.
Among the recombinant human growth hormone varieties, 13 product specifications were successfully declared. Among them, the enterprises applying for powder injection dosage forms (human growth hormone for injection) include four subsidiaries of Changchun High And New Technology Industries (Group) Inc(000661) kinsay pharmaceutical, Anhui Anke Biotechnology (Group)Co.Ltd(300009) , Zhongshan Weiming Haiji and Shanghai United Saier; The most concerned water injection type (recombinant human growth hormone injection) in the industry is only declared by Novo Nordisk, a multinational enterprise, Changchun High And New Technology Industries (Group) Inc(000661) , Anhui Anke Biotechnology (Group)Co.Ltd(300009) both abandoned the bid.
Source: Official Website of Guangdong Pharmaceutical Trading Center
there are early signs of water needle abandonment
On the afternoon of February 21, Changchun High And New Technology Industries (Group) Inc(000661) announced that as of the deadline for the registration of centralized drug procurement of Guangdong alliance, the subsidiary kinsay pharmaceutical had declared three powder specifications, but did not declare the specification of water agent. Anhui Anke Biotechnology (Group)Co.Ltd(300009) the next day, it was also said that the company’s growth hormone products had signed up to participate in the drug centralized purchase of Guangdong alliance, but the specific registration regulations were inconvenient to be disclosed, and the official documents of Guangdong centralized purchase alliance still needed to be announced.
Affected by this, the share prices of the two companies showed an upward trend. Changchun High And New Technology Industries (Group) Inc(000661) on February 22, it once rose by more than 7%. Anhui Anke Biotechnology (Group)Co.Ltd(300009) after opening on February 23, the share price rose sharply, closing up 1.98%.
Previously, affected by the news that growth hormone products were included in the centralized drug purchase of Guangdong alliance, Changchun High And New Technology Industries (Group) Inc(000661) and Anhui Anke Biotechnology (Group)Co.Ltd(300009) share prices fell sharply since January 19, Changchun High And New Technology Industries (Group) Inc(000661) ate three limit sectors in a row, falling 26.7% and Anhui Anke Biotechnology (Group)Co.Ltd(300009) 17.7% in recent 21 trading days.
According to the statistics of Dongguan securities, from the detailed statement of reported volume released on January 19, among the total pre procurement of public medical institutions in the alliance area in the first year of the procurement period, powder injection accounts for about 60% and water injection accounts for 40%. Five powder injection suppliers include Kinsey pharmaceutical, Anhui Anke Biotechnology (Group)Co.Ltd(300009) , Shanghai United Saier, Zhongshan Weiming Haiji and South Korea LG company, of which the pre procurement volume of Anhui Anke Biotechnology (Group)Co.Ltd(300009) powder injection in the first year of the procurement period accounts for more than half; Water injection involves Anhui Anke Biotechnology (Group)Co.Ltd(300009) , Kinsey pharmaceutical and Novo Nordisk. Among them, the pre procurement volume of Kinsey pharmaceutical in the first year of water injection procurement period accounts for 98.24%.
The agency pointed out that the procurement of Guangdong growth hormone alliance will not bid for powder injection dosage forms and water injection dosage forms in groups. The gap between the maximum effective application price of the two dosage forms and products of the same specification is very small, and the price limit rules are relatively strict, resulting in a large expected price reduction of water injection, which exceeds the market expectation. Specifically, the average value of the highest effective application price of 11 specifications of growth hormone powder injection is 14.77 yuan / IU, which is less different from the current market price; The average value of the highest valid application price of 9 specifications of water needle is 12.69 yuan / IU, which is more than 60% different from the price of water needle hanging net of kinsay pharmaceutical in recent years. Therefore, many institutions said that considering the large decline in the highest valid application price of water needle compared with the online price, as well as the price linkage inside and outside the hospital, both Changchun High And New Technology Industries (Group) Inc(000661) and Anhui Anke Biotechnology (Group)Co.Ltd(300009) may give up the application of water needle.
growth hormone market pattern or change
Zhongtai Securities Co.Ltd(600918) previously estimated that the centralized mining scale of Kinsey pharmaceutical and Anhui Anke Biotechnology (Group)Co.Ltd(300009) which obtained the reported volume this time was 117 million yuan and 45.9 million yuan (calculated according to the online price), accounting for a small amount of revenue of the two companies (the revenue of Kinsey pharmaceutical and Anhui Anke Biotechnology (Group)Co.Ltd(300009) in 2020 were 5.8 billion yuan and 1.7 billion yuan respectively), which had little impact on the short-term performance of the company.
Dongguan securities and other institutions further pointed out that in the long run, whether the growth hormone market pattern will be broken mainly depends on the performance of water needle suppliers in the alliance procurement. If some enterprises adopt more radical strategies and some enterprises adopt conservative measures, radical enterprises may open competition channels through the hospital market and seize the hospital market share of unsuccessful enterprises. The impact of the purchase of growth hormone alliance still needs to observe the final decision of enterprises and the results of joint mining.
China Securities News · China Securities Taurus reporter noted that after the release of the centralized purchase news, the above two companies acted frequently. Anhui Anke Biotechnology (Group)Co.Ltd(300009) has repeatedly mentioned on the interactive platform that the company’s new production line with an annual output of 20 million human growth hormone (powder injection) is currently under normal approval. The company also disclosed to the media that the new production line has applied to the drug administration department for production and is expected to be approved by the end of February. In addition, the company plans to produce long-term water needle products in 2022.
Changchun High And New Technology Industries (Group) Inc(000661) also has foresight. In the newly released record of investor relations activities, the company revealed that considering the unique compliance advantages of long-acting growth hormone, the company is stepping up efforts to promote the product. At present, the market expansion momentum and the proportion of long-acting products are in line with the company’s established objectives and expectations. In addition, the company is actively promoting relevant growth hormone products in the field of adult indications, and has made substantial progress. In the future, the field of adult indications will become a new profit growth point of the company.
